title: Progression of visual field in patients with primary open-angle glaucoma - ProgF study 1.
abstract: OBJECTIVE
  To evaluate the visual field rate of progression of patients with treated ocular hypertension (OHT) and primary open-angle glaucoma (POAG) in clinical practice, using the mean deviation (MD) and the visual field index (VFI).
  
  
  METHODS
  Non-interventional cohort study. From a large multicentre database representative of the French population, 441 eyes of 228 patients with treated OHT or POAG followed up at least 6 years with Humphrey 24.2 Sita-Standard visual field examination at least twice a year were identified. From initial data, eyes were classified in five groups: 121 with OHT, 188 with early glaucoma (MD greater than -6 dB), 45 with moderate glaucoma (MD -6 to -12 dB), 41 with advanced glaucoma (MD -12 to -18 dB) and 46 with severe glaucoma (MD less than -18 dB). Rate of progression during the follow-up period was calculated using the trend analysis of the Guided Progression Analysis software.
  
  
  RESULTS
  The mean duration of follow-up was 8.4 ± 2.7 years and the mean number of visual field, 18.4 ± 3.5. In eyes with OHT, rate of progression was -0.09 dB/year (-0.17%VFI/year). In eyes with POAG, rate of progression was -0.32 dB/year (-0.83%VFI/year) in eyes with early glaucoma, -0.52 dB/year (-1.81%VFI/year) in moderate glaucoma, -0.54 dB/year (-2.35%VFI/year) in advanced glaucoma and -0.45 dB/year (-1.97%VFI/year) in severe glaucoma. In eyes with POAG, a significant progression (p < 0.05) was detected in 159 of 320 eyes (49.7%) with trend analysis and 117 of 320 eyes (36.6%, likely progression) or 183 of 320 eyes (57.2%, possible and likely progression) with event analysis.
  
  
  CONCLUSIONS
  Primary open-angle glaucoma is a progressive disease in the majority of patients despite cautioned treatment and follow-up. The rate of progression varies greatly among subjects.
authors.affiliation: Department of Ophthalmology, CHU Grenoble, Université Grenoble Alpes, Grenoble, France.
authors.forename: Florent
authors.initials: F
authors.lastname: Aptel
authors.affiliation: Department of Ophthalmology, CHU Grenoble, Université Grenoble Alpes, Grenoble, France.
authors.forename: Nishal
authors.initials: N
authors.lastname: Aryal-Charles
authors.affiliation: Department of Ophthalmology, HIA du Val de Grâce, Paris, France.
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Giraud
authors.affiliation: Department of Ophthalmology, HIA du Val de Grâce, Paris, France.
authors.forename: Hussam
authors.initials: H
authors.lastname: El Chehab
authors.affiliation: Department of Ophthalmology, HIA du Val de Grâce, Paris, France.
authors.forename: Maxime
authors.initials: M
authors.lastname: Delbarre
authors.affiliation: Department of Ophthalmology, CHU Grenoble, Université Grenoble Alpes, Grenoble, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Chiquet
authors.affiliation: Department of Ophthalmology, CHU Grenoble, Université Grenoble Alpes, Grenoble, France.
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Romanet
authors.affiliation: Department of Ophthalmology, HIA du Val de Grâce, Paris, France.
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Renard
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D005902:Glaucoma, Open-Angle / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D012307:Risk Factors; D014786:Vision Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D058609:Visual Field Tests; D014794:Visual Fields
chemical_list: D000959:Antihypertensive Agents
keywords: event analysis; glaucoma; ocular hypertension; progression; trend analysis; visual field